Prescient Therapeutics Ltd is a small molecule drug development company focused on new cancer drugs. The company's lead compound, PTX-200, inhibits the AKT tumor survival pathway. The company's second compound, PTX-100, blocks a cancer growth enzyme known as geranylgeranyltransferase type 1 (GGT-I). PTX-200 is in a Phase Ib/II trial in breast cancer and a Phase Ib trial in ovarian cancer while a Phase Ib in Acute Myeloid Leukemia (AML) is planned for early 2016. PTX-100 is pre-clinical.
